Abstract
Virion-mediated outbreaks are imminent and despite rapid responses, they continue to cause adverse symptoms and death. Therefore, tunable, sensitive, high-throughput assays are needed to control future virion-mediated outbreaks. Herein, we developed a tunable in situ assay to selectively sort virions and infected host-derived extracellular vesicles (IHD-EVs) and simultaneously detect antigens and nucleic acids at a single-particle resolution. The Biochip Antigen and RNA Assay (BARA) enhanced sensitivities, enabling the detection of virions in asymptomatic patients, genetic mutations in single virions, and the continued long-term expression of virion-RNA in the IHD-EVs of post-acute sequelae of COVID-19 patients. The BARA revealed highly accurate diagnoses by simultaneously detecting the spike glycoprotein and nucleocapsid-encoding RNA on single SARS-CoV-2 virions in saliva and nasopharyngeal swab samples. Altogether, the single-particle detection of antigens and virion-RNA provides a tunable framework for the diagnosis, monitoring, and mutation screening of current and future outbreaks.
Teaser The BARA enables antigenic and nucleic acid testing in single virions for unprecedented perspectives on viral diseases
Competing Interest Statement
E.R. and K.T.N. have filed a patent application for the BARATM technology.
Funding Statement
This work was supported by the U.S. National Institutes of Health (NIH) grants UG3/UH3TR002884 (E.R.) and U18TR003807 (E.R., L.J.L., P.P., K.W., & I.L.). Additional support for E.R. was provided by the William G. Lowrie Department of Chemical and Biomolecular Engineering and the James Comprehensive Cancer Center at The Ohio State University. Additional support includes Kaplan Cancer Research Fund (H.G.K.), Wilke Family Foundation (J.R.H.), the Murdock Trust (J.R.H.), the Parker Institute for Cancer Immunotherapy (J.R.H.), Merck and the Biomedical Advanced Research and Development Authority under Contract HHSO10201600031C (J.R.H.), the Swedish Medical Center Foundation (J.D.G.), DOD W911NF-17-2-0086 (K.W. & I.L.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study relied on patient samples and was approved by the Biomedical Sciences Committee at The Ohio State University (Institutional Review Board protocol 2021H0246). Any patient identifiers were not known to anyone outside the research group to ensure patient privacy.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract updated; figure S9 updated; addition of table S1 and table S10 to clarify the list of antibodies used and molecular beacons designs; re-arrange list of tables in Supplemental file.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
